The Swiss National Bank (SNB) kept its key interest rate at 0%, maintaining low inflation at 0.8% in August, well within its 0%-2% target range. Despite this, market expectations suggest a nearly 50% chance of a rate hike in December and over 90% likelihood of increases by early 2027, driven by recent Swiss franc weakness and rising energy prices. Switzerland's strong franc and unique energy mix have helped contain inflation, but the SNB remains ready to adjust policy to maintain monetary stability. This cautious stance contrasts with other major central banks like the ECB and Fed, which have already begun tightening monetary policy.
The Swiss National Bank's decision to keep rates at 0% comes amid a Financials sector market where 29 of 85 US stocks rose and 52 fell on Pluang. As of Sep 24, 2026 13:11 WIB, notable movers include BMO at USD 170.90 with a 1-day change of -1.98% and 100% sell order activity, FLG at USD 12.30 down 1.91%, and PGR at USD 203.20 down 1.81% but with 100% buy order activity. This snapshot reflects varied investor sentiment within the sector.
A newly created wallet withdrew about $9.93 million worth of cryptocurrency from Binance on September 24. The withdrawal consisted mainly of 814,020 Uniswap (UNI) tokens valued at $7.24 million, along with 2,382 Binance Coin (BNB) worth $1.85 million...
Traders expect the Federal Reserve to raise interest rates four times by June 2027, pushing the federal funds rate to between 4.75% and 5%. This outlook has driven U.S. Treasury yields to new highs, with the 20-year yield nearing 5.5% and the 10-year...
Bitcoin fell below $83,000 on September 24, dropping to $82,874.93 amid rising U.S. 10-year Treasury yields, which reached their highest level since 2007 at 5.11%. This increase in yields has added downward pressure on cryptocurrency prices, with Eth...
The European Central Bank (ECB) has highlighted that speeches and interviews by its policymakers can influence financial markets as much as formal policy decisions. This communication strategy impacts euro-area markets and is now reflected in Bitcoin...
Poolbeg Pharma announced that its POLB 001 TOPICAL clinical trial will proceed as planned following an interim safety review that recommended no changes to the study protocol. The trial, which tests POLB 001 as a preventative treatment for cytokine r...
